[Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA]
- PMID: 929037
[Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA]
Abstract
This study involved twleve parkinsonian patients exposed to abnormal movements provoked by L-DOPA. Including six patients with "mid-dose" dyskinesias and six others with "onset and end of dose" dyskinesias, Correlation between the circumstances of onset of abnormal movements and plasma concentrations of DOPA and O-methyl-DOPA, after administration of a dose of L-DOPA + IDC, gave the following results: 1) mid-dose dyskinesias appeared with the highest plasma concentrations of DOPA, at the maximum therapeutic effect; 2) onset and end of dose occurred during rise and fall in plasma levels of DOPA, coinciding with the relief and the reappearance of parkinsonian symptoms respectively; 3) no correlation could be established between plasma concentrations of O-methyl-DOPA and the duration of the period of clinical remission or of abnormal movements. These biochemical data, completed by the neuropharmacological study of one patient with onset and end of dose abnormal movements suggest the predominant role of a disturbance in central dopaminergic mechanisms in the genesis of abnormal movements, whatever their nature.
Similar articles
-
[Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].Rev Neurol (Paris). 1977 Nov;133(11):627-36. Rev Neurol (Paris). 1977. PMID: 601391 French.
-
["Beginning and end of dose" dyskinesias caused by L-DOPA].Rev Neurol (Paris). 1977 May;133(5):297-308. Rev Neurol (Paris). 1977. PMID: 897439 French.
-
[Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].Rev Neurol (Paris). 1977 Jan;133(1):3-11. Rev Neurol (Paris). 1977. PMID: 847319 French.
-
[Dyskinesia caused by L-DOPA].Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S92-101. Rev Neurol (Paris). 2002. PMID: 12690668 Review. French.
-
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].Rev Neurol (Paris). 2000 Mar;156(3):224-35. Rev Neurol (Paris). 2000. PMID: 10740093 Review. French.
Cited by
-
Clinical pharmacokinetics of anti-parkinsonian drugs.Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002. Clin Pharmacokinet. 1987. PMID: 3311529 Review.
-
Effects of tiapride in tardive dyskinesia.Psychopharmacology (Berl). 1985;85(2):236-9. doi: 10.1007/BF00428422. Psychopharmacology (Berl). 1985. PMID: 3925489 Clinical Trial.
-
Long-term treatment of Parkinson's disease with bromocriptine.J Neurol Neurosurg Psychiatry. 1979 Feb;42(2):143-50. doi: 10.1136/jnnp.42.2.143. J Neurol Neurosurg Psychiatry. 1979. PMID: 422961 Free PMC article.
-
Which factors predict cognitive decline in Parkinson's disease?J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):51-5. doi: 10.1136/jnnp.58.1.51. J Neurol Neurosurg Psychiatry. 1995. PMID: 7823067 Free PMC article.